Skip to Main Content

Paper Details

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.
Clin Cancer Res
45
2021
ATR, AZD6738, Ceralasertib, L1, PATIENTS, PD1, Paclitaxel, Refractory Cancer, advanced cutaneous, acral, and mucosal melanoma, advanced malignancies, anemia, anti-PD1, antitumor, ataxia telangiectasia, ataxia telangiectasia and Rad3-related, ceralasertib, melanoma, neutropenia, p. 4667, paclitaxel, patients, serine, serine/threonine protein kinase, solid tumors, threonine, thrombocytopenia
Author NameAffiliation
Sung Tae KimSungkyunkwan University School of Medicine
Sung Tae KimSungkyunkwan University School of Medicine
Hee Jin ChoInnovative Therapeutic Research Center, Precision Medicine Research Institute, Samsung Medical Center
Kyoung-Mee KimSamsung Medical Center, Sungkyunkwan University School of Medicine
Joon Oh ParkSungkyunkwan University School of Medicine
Jeeyun LeeSungkyunkwan University School of Medicine
Jeeyun LeeSungkyunkwan University
  • 1 - 7

Datasets

Release 1.2